An oncologist, a pulmonologist, and a pathologist discuss multidisciplinary management of advanced NSCLC.
The goal of this activity is to improve knowledge of multidisciplinary care with regard to the use of immune checkpoint inhibitors in advanced non-small cell lung cancer (NSCLC).
This activity is intended for hematology/oncology specialists, pulmonologists, and pathologists.
Approximate Time to Complete: 30 minutes
Credit Available: Dec. 19, 2017 - Dec. 19, 2018
Developed through a partnership between SITC and Medscape.
Upon completion of this activity, participants will be able to:
- Have increased knowledge regarding the individual roles of each multidisciplinary cancer care team member in treating patients with advanced lung cancer
- Have greater competence related to appropriate use of immune checkpoint inhibitors across the continuum of care for patients with advanced non-small cell lung cancer (NSCLC)